Literature DB >> 174489

Prospective double-blind evaluation of topical adenine arabinoside in male herpes progenitalis.

E L Goodman, J P Luby, M T Johnson.   

Abstract

Thirty-four virologically proven episodes of herpes progenitalis in 32 men were treated in a prospective double-blind study with either adenine arabinoside ointment or an identical-appearing placebo for 7 days. Clinical evaluation and quantitative virological studies were done on days 1, 3, and 8. There was a highly significant correlation between clinical response and quantitative virology. There was no difference in clinical or virological response between drug and control groups. Primary attacks tended to have higher viral excretion over the period of observation. The level of complement-fixing antibody to herpes simplex virus type 2(<1:16 versus >/=1:16) in patients with recurrent disease did not appear to alter the course of viral excretion.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 174489      PMCID: PMC429450          DOI: 10.1128/AAC.8.6.693

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Treatment of varicella-zoster virus infections with adenine arabinoside.

Authors:  M T Johnson; R A Buchanan; J P Luby; D Mikulec
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

2.  Effect of adenine arabinoside on cytomegalovirus infections.

Authors:  L T Ch'ien; N J Cannon; R J Whitley; A G Diethelm; W E Dismukes; C W Scott; R A Buchanan; C A Alford
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

3.  In vitro cell transformation by herpesviruses.

Authors:  F Rapp; R Duff
Journal:  Fed Proc       Date:  1972 Nov-Dec

4.  Susceptibility of herpesviruses to three nucleoside analogues and their combinations and enhancement of the antiviral effect of acid pH.

Authors:  M Fiala; A W Chow; K Miyasaki; L B Guze
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

Review 5.  Infection with herpes-simplex viruses 1 and 2. 3.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-10-11       Impact factor: 91.245

6.  A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.

Authors:  D Pavan-Langston; C H Dohlman
Journal:  Am J Ophthalmol       Date:  1972-07       Impact factor: 5.258

7.  A serologic study of herpesvirus hominis strains by microneutralization tests.

Authors:  F P Pauls; W R Dowdle
Journal:  J Immunol       Date:  1967-05       Impact factor: 5.422

8.  Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials.

Authors:  B E Juel-Jensen; F O MacCallum; A M Mackenzie; M C Pike
Journal:  Br Med J       Date:  1970-12-26

9.  Failure of neutral-red photodynamic inactivation in recurrent herpes simplex virus infections.

Authors:  M G Myers; M N Oxman; J E Clark; K A Arndt
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

10.  Preparation of type 2 herpes simplex virus complement-fixing antigen.

Authors:  E L Palmer; M L Martin; D T Warfield
Journal:  Appl Microbiol       Date:  1971-11
  10 in total
  9 in total

1.  Latent herpes simplex virus infections in sensory ganglia of mice after topical treatment with adenine arabinoside and adenine arabinoside monophosphate.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

2.  Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid.

Authors:  E R Kern; J T Richards; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

3.  Resistance to vaginal or systemic infection with herpes simplex virus type 2.

Authors:  M C Breinig; L L Wright; M B McGeorge; P S Morahan
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

Review 4.  The pathogenesis of acute, latent and recurrent herpes simplex virus infections.

Authors:  R J Klein
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

5.  Evaluation of prodrugs of 9-beta-D-arabinofuranosyladenine for therapeutic efficacy in the topical treatment of genital herpesvirus infections in guinea pigs.

Authors:  W M Shannon; G Arnett; D C Baker; S D Kumar; W I Higuchi
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 6.  Antiviral agents: an update--Part I.

Authors:  S Bogger-Goren; P L Ogra
Journal:  Indian J Pediatr       Date:  1980 Sep-Oct       Impact factor: 1.967

7.  Clinical and virologic course of herpes simplex genitalis.

Authors:  Z A Brown; E R Kern; S L Spruance; J C Overall
Journal:  West J Med       Date:  1979-05

Review 8.  Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.

Authors:  R Whitley; C Alford; F Hess; R Buchanan
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

9.  Chemotherapy of genital herpes simplex virus type 2 infections of female hamsters.

Authors:  H E Renis
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.